Pub Date : 2024-05-16DOI: 10.32416/2500-4379-2024-2-16-19
E. Kemel'man
The main aim of the study was to determine the cause of the asymmetric contrast enhancing of the eye muscles in dogs during CT. A group of 200 dogs with asymmetric contrast enhancing of the medial and lateral rectus muscles of the eye was formed. The research showed that regardless of the presence or absence of extracranial pathologies, provided there was no extensive invasion of those into the retrobulbar space, the asymmetric staining of eye muscles is associated with the position of eyeballs. With the eyeball turned laterally, the lateral rectus muscle acquires a more hyperdensive patter, with the eyeball turned medially, the medial rectus and oblique dorsal muscule acquires a more hyperdensive patter. There was not a single case when the difference in staining of the rectus muscles would not correspond to the position of eyeballs. No other reasons that could convincingly explain the pattern of asymmetric staining of eye muscles in dogs were found. This study is the first description of the pattern of asymmetric eye muscle contrast enhancing in dogs on CT.
{"title":"CT pattern of asymmetric contrast enhancing of the eye muscles in dogs with different position of the eyeballs","authors":"E. Kemel'man","doi":"10.32416/2500-4379-2024-2-16-19","DOIUrl":"https://doi.org/10.32416/2500-4379-2024-2-16-19","url":null,"abstract":"The main aim of the study was to determine the cause of the asymmetric contrast enhancing of the eye muscles in dogs during CT. A group of 200 dogs with asymmetric contrast enhancing of the medial and lateral rectus muscles of the eye was formed. The research showed that regardless of the presence or absence of extracranial pathologies, provided there was no extensive invasion of those into the retrobulbar space, the asymmetric staining of eye muscles is associated with the position of eyeballs. With the eyeball turned laterally, the lateral rectus muscle acquires a more hyperdensive patter, with the eyeball turned medially, the medial rectus and oblique dorsal muscule acquires a more hyperdensive patter. \u0000There was not a single case when the difference in staining of the rectus muscles would not correspond to the position of eyeballs. No other reasons that could convincingly explain the pattern of asymmetric staining of eye muscles in dogs were found. \u0000This study is the first description of the pattern of asymmetric eye muscle contrast enhancing in dogs on CT.","PeriodicalId":507008,"journal":{"name":"Russian veterinary journal","volume":"21 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140967816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-16DOI: 10.32416/2500-4379-2024-2-47-51
E. Kornyushenkov
Dexmethedomidine is a selective alpha2-adrenoreceptor agonist with a powerful sedative effect and analgesic properties. High selectivity of dexmedetomide (1620:1) makes it the optimal drug among all representatives of the alpha-2adrenoreceptor agonist class for use in relatively small animals. Dexmedetomidine is currently the most popular sedative used for premedication and sedation, as well as in multimodal analgesia in a constant-rate infusion mode in intensive care. In 2024, a domestic drug with the trade name «Dexody» of the pharmaceutical company «Apicenna» with the active substance dexmethedomidine was registered. The drug is a complete analogue of the original drug and is approved for use in veterinary medicine.
{"title":"Alpha-2adrenoreceptor agonists. Dexmethedomidine","authors":"E. Kornyushenkov","doi":"10.32416/2500-4379-2024-2-47-51","DOIUrl":"https://doi.org/10.32416/2500-4379-2024-2-47-51","url":null,"abstract":"Dexmethedomidine is a selective alpha2-adrenoreceptor agonist with a powerful sedative effect and analgesic properties. High selectivity of dexmedetomide (1620:1) makes it the optimal drug among all representatives of the alpha-2adrenoreceptor agonist class for use in relatively small animals. Dexmedetomidine is currently the most popular sedative used for premedication and sedation, as well as in multimodal analgesia in a constant-rate infusion mode in intensive care. In 2024, a domestic drug with the trade name «Dexody» of the pharmaceutical company «Apicenna» with the active substance dexmethedomidine was registered. The drug is a complete analogue of the original drug and is approved for use in veterinary medicine.","PeriodicalId":507008,"journal":{"name":"Russian veterinary journal","volume":"28 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140967534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-16DOI: 10.32416/2500-4379-2024-2-5-15
Igor' Samoshkin, Il'ya Vilkovyskiy
In the first part of the article based on the literature data, the principles and algorithm of performing femoral radiography in the fronta, plans are systematized, and literary data on the average physiological norms of femoral angles obtained in accordance with the CORA methodology are presented.
{"title":"Radiography and radiographic measurements of the femur based on the CORA methodology. Part 1. Measurements of the femur in the frontal plane","authors":"Igor' Samoshkin, Il'ya Vilkovyskiy","doi":"10.32416/2500-4379-2024-2-5-15","DOIUrl":"https://doi.org/10.32416/2500-4379-2024-2-5-15","url":null,"abstract":"In the first part of the article based on the literature data, the principles and algorithm of performing femoral radiography in the fronta, plans are systematized, and literary data on the average physiological norms of femoral angles obtained in accordance with the CORA methodology are presented.","PeriodicalId":507008,"journal":{"name":"Russian veterinary journal","volume":"32 42","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140966607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Heartworm disease is a vector-borne disease caused by the nematode Dirofilaria immitis, traditionally considered as a disease in dogs. However, it is also detected in cats, although the clinical sings and diagnostic approach to the patient are significantly different. This article discusses some features of the clinical sings, diagnosis and treatment using the example of a clinical case of heartworm disease in a cat.
{"title":"A clinical case of cardiopulmonary dirofilariasis in a cat","authors":"Svetlana Lutchenkova, Natal'ya Mochalova, Vladislava Illarionova","doi":"10.32416/2500-4379-2024-2-20-27","DOIUrl":"https://doi.org/10.32416/2500-4379-2024-2-20-27","url":null,"abstract":"Heartworm disease is a vector-borne disease caused by the nematode Dirofilaria immitis, traditionally considered as a disease in dogs. However, it is also detected in cats, although the clinical sings and diagnostic approach to the patient are significantly different. This article discusses some features of the clinical sings, diagnosis and treatment using the example of a clinical case of heartworm disease in a cat.","PeriodicalId":507008,"journal":{"name":"Russian veterinary journal","volume":"37 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140969734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-16DOI: 10.32416/2500-4379-2024-2-41-46
Svetlana V. Savoyskaya
This study includes clinical data collected from 2016 to 2023. In total, hemoplasmosis was detected in 102 cats (63 females and 39 males) aged from 5 months to 8 years. Of these, 34 cats were diagnosed with a severe form of the disease, and 68 with a mild one. In cats with severe hemoplasmosis, in 45 % of cases, the disease was complicated by chronic renal failure. Also, 5 % of them were chronic carriers of toxoplasmas. Most of the animals were taken from shelters, or were homeless. One of the leading clinical signs of hemoplasmosis is anemia, which develops as a result of mass hemolysis of infected red blood cells. The aim of this work was to eliminate anemia and accelerate the normalization of hematopoiesis in cats with hemoplasmosis. For the treatment of 45 animals (control group), a standard therapy regimen was used, which included antibiotics and glucocorticoids, whereas for therapy regimen of remaining 57 cats (experimental group) Gamavit and Phosprenyl were added. Using this therapeutic scheme, early relief of anemia, stimulation of erythropoiesis, restoration of blood formula and normalization of liver function were noted as well as acceleration of clinical recovery of sick animals which occurred faster by 4…5 days.
{"title":"Supplementation of feline hemoplasmosis treatment protocol with Gamavit and Phosprenyl increases the effectiveness of anemia correction: a retrospective analysis","authors":"Svetlana V. Savoyskaya","doi":"10.32416/2500-4379-2024-2-41-46","DOIUrl":"https://doi.org/10.32416/2500-4379-2024-2-41-46","url":null,"abstract":"This study includes clinical data collected from 2016 to 2023. In total, hemoplasmosis was detected in 102 cats (63 females and 39 males) aged from 5 months to 8 years. Of these, 34 cats were diagnosed with a severe form of the disease, and 68 with a mild one. In cats with severe hemoplasmosis, in 45 % of cases, the disease was complicated by chronic renal failure. Also, 5 % of them were chronic carriers of toxoplasmas. Most of the animals were taken from shelters, or were homeless. \u0000One of the leading clinical signs of hemoplasmosis is anemia, which develops as a result of mass hemolysis of infected red blood cells. \u0000The aim of this work was to eliminate anemia and accelerate the normalization of hematopoiesis in cats with hemoplasmosis. \u0000For the treatment of 45 animals (control group), a standard therapy regimen was used, which included antibiotics and glucocorticoids, whereas for therapy regimen of remaining 57 cats (experimental group) Gamavit and Phosprenyl were added. Using this therapeutic scheme, early relief of anemia, stimulation of erythropoiesis, restoration of blood formula and normalization of liver function were noted as well as acceleration of clinical recovery of sick animals which occurred faster by 4…5 days.","PeriodicalId":507008,"journal":{"name":"Russian veterinary journal","volume":"54 20","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140969325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-16DOI: 10.32416/2500-4379-2024-2-35-40
Syergyey YEngashyev, Ekaterina Engasheva, Aleksey Savinkov, Konstantin Sadov, Denis Novikov
The purpose of the research was to study the effectiveness of a new medicinal product for veterinary use «MASTIBLOCK gel» in the treatment of mastitis in cows during lactation. 5 groups (10 animals each) of lactating cattle with various forms of mastitis were formed: group 1 – subclinical mastitis; group 2 – acute serous mastitis; group 3 – chronic serous mastitis; group 4 – acute catarrhal mastitis; group 5 – chronic catarrhal mastitis. For the 1st, 2nd and 4th groups, therapy was carried out for 7 days, for the 3rd and 5th – for 14 days. The drug was used externally for all animals, by applying a uniform layer of 50 g 2 times a day to the surface of the udder. At the beginning and end of treatment, blood was taken in each group for general blood test; milk was taken to assess bacterial contamination and assess the number of somatic cells. The clinical assessment of the condition of the animals was carried out daily. All the animals were kept in the same conditions. The diet of cows of all groups corresponded to the norms for this type and technological use of animals. The presence of pathology and the effectiveness of the drug were evaluated based on the results of a clinical examination of animals, the results of bacteriological analysis, a general blood test and a milk test for the number of somatic cells. As a result of the work carried out, based on the results of the study, it was found that the drug showed high therapeutic efficacy in various forms of mastitis caused by opportunistic microflora in lactating cows, and also helps to restore the qualitative characteristics of milk and reduce somatic cells in them.
{"title":"Efficacy of MASTIBLOCK Gel in the treatment of mastitis in cattle during lactation","authors":"Syergyey YEngashyev, Ekaterina Engasheva, Aleksey Savinkov, Konstantin Sadov, Denis Novikov","doi":"10.32416/2500-4379-2024-2-35-40","DOIUrl":"https://doi.org/10.32416/2500-4379-2024-2-35-40","url":null,"abstract":"The purpose of the research was to study the effectiveness of a new medicinal product for veterinary use «MASTIBLOCK gel» in the treatment of mastitis in cows during lactation. 5 groups (10 animals each) of lactating cattle with various forms of mastitis were formed: group 1 – subclinical mastitis; group 2 – acute serous mastitis; group 3 – chronic serous mastitis; group 4 – acute catarrhal mastitis; group 5 – chronic catarrhal mastitis. For the 1st, 2nd and 4th groups, therapy was carried out for 7 days, for the 3rd and 5th – for 14 days. The drug was used externally for all animals, by applying a uniform layer of 50 g 2 times a day to the surface of the udder. At the beginning and end of treatment, blood was taken in each group for general blood test; milk was taken to assess bacterial contamination and assess the number of somatic cells. The clinical assessment of the condition of the animals was carried out daily. All the animals were kept in the same conditions. The diet of cows of all groups corresponded to the norms for this type and technological use of animals. \u0000The presence of pathology and the effectiveness of the drug were evaluated based on the results of a clinical examination of animals, the results of bacteriological analysis, a general blood test and a milk test for the number of somatic cells. \u0000As a result of the work carried out, based on the results of the study, it was found that the drug showed high therapeutic efficacy in various forms of mastitis caused by opportunistic microflora in lactating cows, and also helps to restore the qualitative characteristics of milk and reduce somatic cells in them.","PeriodicalId":507008,"journal":{"name":"Russian veterinary journal","volume":"43 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140969960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-16DOI: 10.32416/2500-4379-2024-2-28-34
Elena Elizarova, D. Beloglazov, S. Mukaseev, O. Zeynalov
The treatment by Kurs Uspokoin tablets in a minimum initial daily dose of 7 mg/kg for the first three days, with a further increase to 14 mg/kg, showed a positive effect in correcting the behavior of older cats with progressive simptoms of cognitive disfunction. During the treatment were registered a statistically and clinically significant decrease in idiopathic vocalization, restoration of sleep cycles and wakefulness, elimination of house-soiling behavior, disorientation, increased activity, and improvement of social behavior. During the treatment by Kurs Uspokoin tablets and after its discontinuation no adverse reactions were registered.
{"title":"Evaluation of the effectiveness of a new drug Kurs Uspokoin tablets for the correction of age-related cognitive impairment in cats","authors":"Elena Elizarova, D. Beloglazov, S. Mukaseev, O. Zeynalov","doi":"10.32416/2500-4379-2024-2-28-34","DOIUrl":"https://doi.org/10.32416/2500-4379-2024-2-28-34","url":null,"abstract":"The treatment by Kurs Uspokoin tablets in a minimum initial daily dose of 7 mg/kg for the first three days, with a further increase to 14 mg/kg, showed a positive effect in correcting the behavior of older cats with progressive simptoms of cognitive disfunction. During the treatment were registered a statistically and clinically significant decrease in idiopathic vocalization, restoration of sleep cycles and wakefulness, elimination of house-soiling behavior, disorientation, increased activity, and improvement of social behavior. \u0000During the treatment by Kurs Uspokoin tablets and after its discontinuation no adverse reactions were registered.","PeriodicalId":507008,"journal":{"name":"Russian veterinary journal","volume":"27 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140969411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-28DOI: 10.32416/2500-4379-2024-1-5-11
E. Kornyushenkov, Dar'ya Vdovina, Polina Anisimova, A. Shimshirt, Ekaterina Viktorova
This article presents the results of an original study on the therapeutic equivalence of the domestic drug «Vesotil®» based on a combination of drugs tiletamine-zolazepam, an analog drug «Zoletil® 100». «Vesotil®» was used as the main anesthetic for 28 animals (dogs and cats) undergoing surgery. «Vesotil®» has proven to be a safe and reliable drug, not inferior to the original one.
{"title":"The pilot comparative clinical study of the anesthetic activity of a new domestic drug based on tiletamine-zolazepam «Vesotil®» and its original analogue «Zoletil® 100»","authors":"E. Kornyushenkov, Dar'ya Vdovina, Polina Anisimova, A. Shimshirt, Ekaterina Viktorova","doi":"10.32416/2500-4379-2024-1-5-11","DOIUrl":"https://doi.org/10.32416/2500-4379-2024-1-5-11","url":null,"abstract":"This article presents the results of an original study on the therapeutic equivalence of the domestic drug «Vesotil®» based on a combination of drugs tiletamine-zolazepam, an analog drug «Zoletil® 100». «Vesotil®» was used as the main anesthetic for 28 animals (dogs and cats) undergoing surgery. «Vesotil®» has proven to be a safe and reliable drug, not inferior to the original one.","PeriodicalId":507008,"journal":{"name":"Russian veterinary journal","volume":"136 37","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140423127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-28DOI: 10.32416/2500-4379-2024-1-33-39
Elena Elizarova, D. Beloglazov, O. Zeynalov, S. Mukaseev
The use of the drug Kurs Uspokoin tablets in a minimum initial daily dose of 7 mg/kg for the first three days, with a further increase in the minimum daily dose to 14 mg/kg, showed a positive effect in correcting the behavior of dogs older than 10 years with progressive signs of cognitive impairment.
{"title":"Evaluation of the effectiveness of a new drug Kurs Uspokoin tablets for the correction of age-related cognitive impairment in dogs","authors":"Elena Elizarova, D. Beloglazov, O. Zeynalov, S. Mukaseev","doi":"10.32416/2500-4379-2024-1-33-39","DOIUrl":"https://doi.org/10.32416/2500-4379-2024-1-33-39","url":null,"abstract":"The use of the drug Kurs Uspokoin tablets in a minimum initial daily dose of 7 mg/kg for the first three days, with a further increase in the minimum daily dose to 14 mg/kg, showed a positive effect in correcting the behavior of dogs older than 10 years with progressive signs of cognitive impairment.","PeriodicalId":507008,"journal":{"name":"Russian veterinary journal","volume":"21 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140418363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-28DOI: 10.32416/2500-4379-2024-1-40-44
Roman Leonard, Syergyey YEngashyev, Aleksandr Komarov, Aleksandr Muromcev, A. Mironenko, Yuliya Aleksandrova
The article describes a tolerability study of the new drug Nephrospas, which contains telmisartan and excipients. The trial was conducted in cats with multiple daily administration at five times the therapeutic dose for 1 month (30 days). Two groups of animals were formed: experimental (10 cats) and control (7 cats). Animals of the experimental group were administered Nephrospas in a fivefold therapeutic dose of 0.5 ml/kg live weight of a cat orally during 30 days immediately after feeding. Animals of the control group were not administered the drug. Before the start of the experiment (day 0), on the 31st and 56th days of the experiment, weighing, thermometry, pulse and respiratory rates, blood pressure were determined, blood samples were taken for hematological studies (general clinical blood test, biochemical blood analysis), urine samples were taken for physical examination. chemical research. Based on the results of the conducted studies, it can be concluded that the drug Nephrospas is safe for cats when administered in excessive doses, as the use of the drug in a fivefold therapeutic dose does not adversely affect the general condition of animals, dynamics of body weight, blood pressure, does not change body temperature, morphological composition and biochemical parameters of blood, general clinical parameters of cat urine.
{"title":"Study of the drug Nephrospas tolerability in cats","authors":"Roman Leonard, Syergyey YEngashyev, Aleksandr Komarov, Aleksandr Muromcev, A. Mironenko, Yuliya Aleksandrova","doi":"10.32416/2500-4379-2024-1-40-44","DOIUrl":"https://doi.org/10.32416/2500-4379-2024-1-40-44","url":null,"abstract":"The article describes a tolerability study of the new drug Nephrospas, which contains telmisartan and excipients. The trial was conducted in cats with multiple daily administration at five times the therapeutic dose for 1 month (30 days). \u0000Two groups of animals were formed: experimental (10 cats) and control (7 cats). Animals of the experimental group were administered Nephrospas in a fivefold therapeutic dose of 0.5 ml/kg live weight of a cat orally during 30 days immediately after feeding. Animals of the control group were not administered the drug. \u0000 \u0000Before the start of the experiment (day 0), on the 31st and 56th days of the experiment, weighing, thermometry, pulse and respiratory rates, blood pressure were determined, blood samples were taken for hematological studies (general clinical blood test, biochemical blood analysis), urine samples were taken for physical examination. chemical research. \u0000Based on the results of the conducted studies, it can be concluded that the drug Nephrospas is safe for cats when administered in excessive doses, as the use of the drug in a fivefold therapeutic dose does not adversely affect the general condition of animals, dynamics of body weight, blood pressure, does not change body temperature, morphological composition and biochemical parameters of blood, general clinical parameters of cat urine.","PeriodicalId":507008,"journal":{"name":"Russian veterinary journal","volume":"26 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140419989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：